News

Biotronik, Passeo-18 Lux, DCB, BIOLUX P-I, trial, drug eluting, balloon catheter

Biotronik announced that results of its BIOLUX P-I clinical study have been published in the Journal of Endovascular Therapy. BIOLUX P-I was a prospective, international, multi-center,...

In.PACT Admiral, PAD, Medicare, pass-through payment, Medtronic, balloon cath

Medtronic announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved a transitional pass-through payment for the company’s IN.PACT Admiral drug-coated balloon (DCB)...

Bard, Lutonix, drug coated balloon, DCB, CMS, pass-through payment, outpatient

C. R. Bard Inc. announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved a pass-through payment for the Lutonix drug-coated balloon (DCB) under the Medicare hospital...

Lutonix, drug eluting balloon, drug coated balloon

Drug-eluting balloons (DEBs) have been one of the long-awaited new transcatheter technologies to help reduce high restenosis rates in peripheral artery disease (PAD). The U.S. Food and Drug...

Boston Scientific, Bard, Lutonix, DCB, drug coated balloon, distribute

Boston Scientific and C. R. Bard announced a deal where Boston Scientific will distribute the Lutonix 035 drug coated balloon (DCB) percutaneous transluminal angioplasty catheter in the...

Medtronic, In.Pact Admiral DCB, PAD, U.S. launch, drug-coated balloon

United States hospitals began using a new medical device from Medtronic plc  called the In.Pact Admiral drug-coated balloon (DCB) to treat patients with peripheral arterial disease (PAD) in...

drug-eluting balloons, DEB, ECRI, report, peripheral artery disease, PAD, cath

ECRI Institute has created a report that offers an overview of drug-eluting balloon (DEB) technology, “Health Technology Forecast report, "Drug-eluting Angioplasty Balloons for...

Covidien announced it has received CE Mark approval for its Stellarex drug-coated angioplasty balloon (DCB). 

Medtronic, In.Pact, Admiral drug-coated balloon, DCB, drug-eluting balloon

The U.S. Food and Drug Administration (FDA) has cleared Medtronic’s In.Pact Admiral drug-coated balloon (DCB) for the interventional treatment of peripheral artery disease (PAD) for the...

balloon catheters, clinical trial/study, medtronic, IN.PACT Admiral drug-coated

The results of a landmark study published this month in Circulation indicate that a device from Medtronic Inc. called the IN.PACT Admiral drug-coated balloon (DCB) significantly...

Cardionovum GmbH announced that it has initiated a 150-patient clinical study of its novel paclitaxel-releasing, high-pressure shunt balloon dilatation catheter, Aperto.

Covidien releases 12-month results of the DEFINITIVE AR study, the first randomized study designed to identify the clinical benefits of plaque removal using directional atherectomy ...

Optimizing the treatment of coronary artery disease with a new foundation for future stent innovations, Medtronic Inc. announces CE mark and international launch of the Resolute Onyx ...

For the treatment of peripheral artery disease in leg arteries above the knee, the IN.PACT Admiral ...

Metro Health (Michigan) cardiovascular specialist Jihad Mustapha, M.D., is one of the first physicians in the United States to use a new medical device to treat peripheral artery disease (PAD).

Restenosis, the recurrence of narrowing of the arteries after stenting, is a common risk of this endovascular treatment. There are no well-defined guidelines to treat restenosis, but recent...

Medtronic IN.PACT Admiral Drug Coated Balloon Peripheral Artery Disease Treatmen

Presented for the first time at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) conference, the latest clinical and economic data on the IN.PACT Admiral drug-coated balloon (DCB)...

FDA Clears Lutonix 035 Drug Coated Balloon C.R. Bard Inc.

C. R. Bard Inc. announced the U.S. Food and Drug Administration (FDA) approval of the Lutonix 035 drug-coated balloon (DCB) catheter for percutaneous transluminal angioplasty (PTA) after pre-...

A new clinical trial comparing the use of everolimus-eluting stents (EES) and drug-eluting balloons (DEB) in treating in-stent restenosis (ISR) from drug-eluting stents found that EES provided...

Boston Scientific Corp. CE mark Ranger Ranger Paclitaxel-coated PTA Balloon Cath

Boston Scientific received CE mark for the Ranger Paclitaxel-coated PTA Balloon Catheter. The technology is now in full European market launch.